Aripiprazole Accord
aripiprazole
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Aripiprazole Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Aripiprazole Accord.
For practical information about using Aripiprazole Accord, patients should read the package leaflet or contact their doctor or pharmacist.
-
List item
Aripiprazole Accord : EPAR - Summary for the public (PDF/186.84 KB)
First published: 27/11/2015
Last updated: 27/11/2015
EMA/634874/2015 -
-
List item
Aripiprazole Accord : EPAR - Risk-management-plan summary (PDF/108.13 KB)
First published: 27/11/2015
Last updated: 27/11/2015
EMA/16634/2014
Authorisation details
Product details | |
---|---|
Name |
Aripiprazole Accord
|
Agency product number |
EMEA/H/C/004021
|
Active substance |
aripiprazole
|
International non-proprietary name (INN) or common name |
aripiprazole
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
N05AX12
|
Generic |
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines. |
Publication details | |
---|---|
Marketing-authorisation holder |
Accord Healthcare S.L.U.
|
Revision |
15
|
Date of issue of marketing authorisation valid throughout the European Union |
15/11/2015
|
Contact address |
Accord Healthcare S.L.U. |
Product information
11/07/2022 Aripiprazole Accord - EMEA/H/C/004021 - IB/0026
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Psycholeptics
Therapeutic indication
Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.
Aripiprazole Accord is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.
Aripiprazole Accord is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.